Shanghai Henlius Biotech, Inc. 2696.HK Stock
Shanghai Henlius Biotech, Inc. Price Chart
Shanghai Henlius Biotech, Inc. 2696.HK Financial and Trading Overview
Shanghai Henlius Biotech, Inc. stock price | 14.86 HKD |
Previous Close | 11.52 HKD |
Open | 11.9 HKD |
Bid | 11.52 HKD x N/A |
Ask | 11.76 HKD x N/A |
Day's Range | 11.18 - 11.9 HKD |
52 Week Range | 10.02 - 19.04 HKD |
Volume | 83.6K HKD |
Avg. Volume | 136.97K HKD |
Market Cap | 6.26B HKD |
Beta (5Y Monthly) | 0.872185 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 1.08 HKD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.72 HKD |
2696.HK Valuation Measures
Enterprise Value | 9.07B HKD |
Trailing P/E | N/A |
Forward P/E | -67.76471 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.9476168 |
Price/Book (mrq) | 3.8259716 |
Enterprise Value/Revenue | 2.82 |
Enterprise Value/EBITDA | -41.065 |
Trading Information
Shanghai Henlius Biotech, Inc. Stock Price History
Beta (5Y Monthly) | 0.872185 |
52-Week Change | -37.72% |
S&P500 52-Week Change | 20.43% |
52 Week High | 19.04 HKD |
52 Week Low | 10.02 HKD |
50-Day Moving Average | 12.71 HKD |
200-Day Moving Average | 13.12 HKD |
2696.HK Share Statistics
Avg. Volume (3 month) | 136.97K HKD |
Avg. Daily Volume (10-Days) | 91.99K HKD |
Shares Outstanding | 163.43M |
Float | 68.33M |
Short Ratio | N/A |
% Held by Insiders | 28.24% |
% Held by Institutions | 32.97% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -21.62% |
Operating Margin (ttm) | -13.35% |
Gross Margin | 73.72% |
EBITDA Margin | -6.86% |
Management Effectiveness
Return on Assets (ttm) | -3.33% |
Return on Equity (ttm) | -35.35% |
Income Statement
Revenue (ttm) | 3.21B HKD |
Revenue Per Share (ttm) | 5.93 HKD |
Quarterly Revenue Growth (yoy) | 83.59% |
Gross Profit (ttm) | N/A |
EBITDA | -220772992 HKD |
Net Income Avi to Common (ttm) | -695259008 HKD |
Diluted EPS (ttm) | -1.47 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 872.06M HKD |
Total Cash Per Share (mrq) | 1.61 HKD |
Total Debt (mrq) | 3.68B HKD |
Total Debt/Equity (mrq) | 224.72 HKD |
Current Ratio (mrq) | 0.438 |
Book Value Per Share (mrq) | 3.011 |
Cash Flow Statement
Operating Cash Flow (ttm) | 981.62M HKD |
Levered Free Cash Flow (ttm) | -733845120 HKD |
Profile of Shanghai Henlius Biotech, Inc.
Country | Hong Kong |
State | N/A |
City | Shanghai |
Address | Innov Tower (Capitaland Building) |
ZIP | 200233 |
Phone | 86 21 3339 5800 |
Website | https://www.henlius.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 3406 |
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, NSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX41, HLX35, HLX208, HLX53, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and HNSCC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, HCC, renal cell carcinoma, and mCRC; and HLX15 for multiple myeloma. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Q&A For Shanghai Henlius Biotech, Inc. Stock
What is a current 2696.HK stock price?
Shanghai Henlius Biotech, Inc. 2696.HK stock price today per share is 14.86 HKD.
How to purchase Shanghai Henlius Biotech, Inc. stock?
You can buy 2696.HK shares on the HKSE exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Shanghai Henlius Biotech, Inc.?
The stock symbol or ticker of Shanghai Henlius Biotech, Inc. is 2696.HK.
Which industry does the Shanghai Henlius Biotech, Inc. company belong to?
The Shanghai Henlius Biotech, Inc. industry is Biotechnology.
How many shares does Shanghai Henlius Biotech, Inc. have in circulation?
The max supply of Shanghai Henlius Biotech, Inc. shares is 543.49M.
What is Shanghai Henlius Biotech, Inc. Price to Earnings Ratio (PE Ratio)?
Shanghai Henlius Biotech, Inc. PE Ratio is 13.75925800 now.
What was Shanghai Henlius Biotech, Inc. earnings per share over the trailing 12 months (TTM)?
Shanghai Henlius Biotech, Inc. EPS is 1.08 HKD over the trailing 12 months.
Which sector does the Shanghai Henlius Biotech, Inc. company belong to?
The Shanghai Henlius Biotech, Inc. sector is Healthcare.
Shanghai Henlius Biotech, Inc. 2696.HK included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nasdaq EM Plus Korea Small Cap NQEMKRSCGBP | 1476.35 GBP 1888.16 USD |
<0.01
|
— — | 1476.35 GBP 1888.16 USD | 1476.35 GBP 1888.16 USD | — - | — — |
- {{ link.label }} {{link}}